Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adverum Biotechnologies, Inc.
This is a multi-center study to evaluate the long-term safety and tolerability of a single intravitreal (IVT) injection of ADVM-022 in a preceding "parent" study, ADVM-022-04 \[INFINITY\]. Participants will be followed for a total of 5 years post- ADVM-022 administration (inclusive of the parent study). There is no investigational treatment administered in this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have participated in the ADVM-022-04 \[INFINITY\] (parent) study and received ADVM-022
Must provide signed informed consent
Must be willing and able to comply with all study procedures
You may not be if
\- None
Clareo Health | Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
